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Pancreatitis is the most common adverse event of endoscopic retrograde cholangiopancreatography, with the
potential for clinically significant morbidity and mortality. Several patient and procedural risk factors have
been identified that increase the risk of posteendoscopic retrograde cholangiopancreatography pancreatitis
(PEP). Considerable research efforts have identified several pharmacologic and procedural interventions that
can drastically affect the incidence of PEP. This review article addresses the underlying mechanisms at play for
the development of PEP, identifying patient and procedural risk factors and meaningful use of risk-
stratification information, and details current interventions aimed at reducing the risk of this complication.
ª 2016 Mayo Foundation for Medical Education and Research n Mayo Clin Proc. 2017;92(3):434-448P ancreatitis remains the most commonadverse event of endoscopic retrogradecholangiopancreatography (ERCP),
with the potential for substantial morbidity
and mortality.1-4 Several large clinical studies
have reported the incidence of post-ERCP
pancreatitis (PEP) to be 3% to 5%.5,6 A recent
meta-analysis composed of 21 prospective
studies found the incidence of PEP to be
consistent with previously described studies
at approximately 3.5%7; however, PEP rates
ranged from 1% to nearly 16% depending
on patient selection.6,8 There are several pa-
tient- and procedure-related factors that have
been identified to increase the risk of PEP.
The presence of multiple factors can have a
cumulative effect. As a result, several chemical
and procedural interventions have been stud-
ied in the hopes of decreasing PEP rates. Here-
in, we describe the potential mechanisms of
pancreatic injury during ERCP, review patient-
and procedure-related risk factors, and discuss
the latest studies involving pharmacologic and
procedural interventions aimed at reducing
the rates of PEP.
MECHANISMS OF PEP
There are several potential underlying mecha-
nisms of pancreatic injury during ERCP,
including mechanical, thermal, chemical, hy-
drostatic, enzymatic, andmicrobiologic insults.9
Prolonged manipulation of the papillary orifice,
difficult cannulation of the biliary tree, and
repeated inadvertent instrumentation of the
pancreatic duct result in ductal injury or injury
to the ampulla.10-12 Thermal injury may resultMayo Clin Proc. n March 2017
www.mayoclinicproceedings.org nfrom electrocautery current used during sphinc-
terotomy (biliary or pancreatic), endoscopic
papillectomy, or ablation of neoplastic lesions
in the region of the ampulla of Vater.13,14 Resul-
tant papillary edema caused by mechanical or
thermal injury is thought to obstruct the
outflow of pancreatic secretion, resulting in
pancreatitis. Contrast agents could potentially
lead to PEP by causing chemical injury; how-
ever, the data remain controversial.15 George
et al15 performed a meta-analysis to determine
whether the osmolality of contrast media used
affects the incidence of PEP. Thirteen random-
ized controlled trials (RCTs) were included
comparing the incidence of PEP (defined as
pancreatic enzyme levels elevated 3 times above
their upper limits of normal [ULNs] and typical
pancreatic pain) with the use of high- vs low-
osmolality contrast media. Using logistic regres-
sion, they found no significant difference in PEP
rates between low- and high-osmolality contrast
media. Hydrostatic injury, which results from
overinjection of the pancreatic duct or infusion
of water or saline through manometry catheters,
is thought to be one of the most important
causes of PEP.14,16 Introduction of foreignmate-
rial into the pancreatic duct results in the intra-
luminal activation of proteolytic enzymes,
which subsequently results in enzymatic injury.
In addition, the reflux pathogenesis describes
the introduction of intestinal enzymes into the
pancreatic ductal tree by ERCP.17 It is thought
that contrast agents, not currently used in clin-
ical practice, may activate intracellular trypsin,
with resultant PEP. Last, bacterial translocation
and subsequent activation of the inflammatory;92(3):434-448 n http://dx.doi.org/10.1016/j.mayocp.2016.10.028
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d The development of posteendoscopic retrograde chol-
angiopancreatography pancreatitis (PEP) is thought to be multi-
factorial, including mechanical, thermal, chemical, hydrostatic,
enzymatic, and microbiologic insults. Thus, chemoprophylaxis and
procedural techniques to prevent PEP should take all these factors
into account.
d The risk of PEP in low- and high-risk patients is greater than 5%
and 16%, respectively. To minimize this risk, clinicians must
choose appropriate patients, use endoscopic retrograde chol-
angiopancreatography pancreatitis almost exclusively as a ther-
apeutic procedure, use sound procedural techniques, and
consider the administration of rectal indomethacin, the use of
aggressive hydration, or the placement of pancreatic stents.
d Large randomized controlled trials are necessary to further
define which patient populations derive benefit from rectal
indomethacin therapy and to define the role of pancreatic duct
stent placement in low-risk patients.
THE SCOPE OF POST-ERCP PANCREATITIScascade is also thought to contribute to the path-
ogenesis of PEP.18 These underlying mecha-
nisms may work independently or in concert,
resulting in a cascade of events that activate pro-
teolytic enzymes, promote autodigestion, and
impair acinar secretion, with subsequent clinical
manifestations of the local and systemic effects
of pancreatitis.19-21 Therefore, most preventive
therapies are aimed at interrupting various trig-
gers of this cascade.
RISK FACTORS AND MEANINGFUL USE OF
RISK-STRATIFICATION INFORMATION
Several studies have identified factors that in-
crease the risk of PEP, which can be divided
into patient- and procedure-related factors.
Table 13,22-26 summarizes expert consensus,
based on several clinical trials, of independent
risk factors for PEP. There are several other fac-
tors that have been suggested to be possible
risk factors for PEP but that have not yet been
universally accepted as independent risk factors,
including self-expanding metal stent place-
ment,27 pancreatic deep wire passage,28 and
intraductal papillary mucinous neoplasm.26
These risk factors seem to have a synergistic ef-
fect, as evidenced by Freeman et al,9 who found
the risk of PEP in a young woman with clinical
suspicion of sphincter of Oddi dysfunction, a
normal bilirubin level, and difficultywith cannu-
lation to be in excess of 40%. This particular sub-
set of patients (women with suspected sphincter
of Oddi dysfunction) not only is at an increased
risk for PEP but also seems to develop more
severe PEP, and studies have found there to be
a higher mortality rate as well.1,9,29
In addition, the individual endoscopist’s
procedure volume and level of training have
been implicated as independent risk factors
for PEP. A study by Loperfido et al30 evaluated
the adverse events of diagnostic and therapeutic
ERCP in 2769 patients at medical centers in
Italy during a 2-year period. Of the 9 centers,
6 were considered to be small because they
performed ERCP on fewer than 200 patients
annually. Low volume was identified as an
independent risk factor for overall major
adverse events of therapeutic ERCP, which sup-
ported a policy of centralization of ERCP in
referral centers to limit potential adverse events.
Other multicenter studies, however, have not
confirmed this trend, which is thought to be
due to the fact that low-volume endoscopistsMayo Clin Proc. n March 2017;92(3):434-448 n http://dx.doi.org/10
www.mayoclinicproceedings.orghave a tendency to perform lower-risk proced-
ures.1,9,31 Nevertheless, we recommend that
high-risk cases (based on patient-related risk
factors or anticipated high-risk procedural in-
terventions) be referred to tertiary and quater-
nary medical centers, where a high-volume
endoscopist can perform the procedure.
Thus, it is imperative for the endoscopist
to understand the aforementioned risk factors
and incorporate them into clinical decision
making. The clinical endoscopist can gauge
the risk, in part, of PEP based on nonmodifi-
able patient-related risk factors. This allows
for appropriate case selection and improved
patient relations regarding discussing the
risk-benefit ratio of the procedure. In addition,
combining procedure- and patient-related risk
factors allows for global assessment of a pa-
tient’s overall risk of PEP, which could help
further guide management (ie, postprocedural
hospital admission for further observation in a
patient deemed to be at high risk for PEP).DIAGNOSIS, SEVERITY, AND MANAGEMENT
OF POST-ERCP PANCREATITIS
To date, there are no standardized diagnostic
criteria for PEP; however, the consensus
guidelines proposed by Cotton et al32 are the.1016/j.mayocp.2016.10.028 435
TABLE 2. Severity of Pos
Pancreatitis32
Factor Mil
Length of
hospitalization (d)
<3
Other defining
characteristics
No
TABLE 1. General Consensus of Risk Factors for PEP9,22-26
Patient-related factors Procedure-related factors
Operator-related
factors
Female sex Ampullectomy Inadequate training
Normal serum bilirubin
level
Biliary balloon sphincteroplasty Lack of experience
History of PEP Difficult cannulation
Recurrent pancreatitis Minor papilla sphincterotomy
Sphincter of Oddi
dysfunction
Pancreatic duct injection
Younger age (<60 y) Pancreatic sphincterotomy
Precut sphincterotomy
Sphincter of Oddi manometry
Trainee involvement
PEP ¼ posteendoscopic retrograde cholangiopancreatography pancreatitis.
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436most generally used. Per Cotton et al,32 the
diagnosis of PEP is defined as the presence
of pancreatitis (new pancreatic-type abdom-
inal pain accompanied by at least a threefold
increase in the serum amylase level) that has
developed de novo 24 hours after ERCP. If
the diagnosis of PEP remains in doubt,
contrast-enhanced computed tomography
(CT) of the abdomen or magnetic resonance
imaging (if renal function precludes CT)
should be performed to make the diagnosis.
However, a normal CT finding does not
exclude mild pancreatitis.
Early diagnosis of PEP may be possible by
evaluating serum amylase or lipase levels
within 6 hours of the procedure.33-35 Ito
et al33 evaluated the relationship between the
change in serum amylase levels and PEP. Serum
amylase concentrations were measured before
and 3, 6, and 24 hours after the procedure in
1291 ERCP-related procedures. Forty-seven
patients (3.6%) developed PEP. Subgroup anal-
ysis revealed that 3 hours after the procedure,teEndoscopic Retrograde Cholangiopancreatography
d Moderate Severe
4-10 >10
ne None Hemorrhagic pancreatitis
Pancreatic necrosis or pseudocyst
Necessity for intervention
(percutaneous drainage or surgery)
Mayo Clin Proc. n March 20171% of patients with normal serum amylase
levels and 1%, 5%, 20%, 31%, and 39% of
patients with amylase levels elevated 1 to
2ULN, 2 to 3ULN, 3 to 5ULN, 5 to
10ULN, and more than 10ULN developed
PEP, respectively. Of 143 patients with elevated
serum amylase levels 3 hours after the proced-
ure that remained elevated 6 hours after the
procedure, 37 (25.9%) developed PEP.
Conversely, of 45 patients with elevated serum
amylase levels 3 hours after the procedure
(>2ULN) with subsequent decrease of serum
amylase concentrations 6 hours after the pro-
cedure, only 4 (8.9%) developed PEP. This
led to the conclusion that PEP is associated
with an increase in serum amylase concentra-
tions greater than 2ULN 3 hours after the
procedure with sustained elevation 6 hours
after the procedure and that a decrease in
amylase levels 6 hours after the procedure sug-
gests a decreased likelihood of developing PEP.
The severity of PEP is mainly based on
the length of hospitalization, as illustrated in
Table 2.32 Because the management of PEP is
similar to that of other causes of acute pancre-
atitis, the same prognostic indicators apply to
PEP as to other causes of acute pancreatitis.
Several scoring systems have been validated
in predicting the severity of pancreatitis,
including the bedside index for severity in
acute pancreatitis (BISAP),36 Acute Physiology
and Chronic Health Examination II score,37
Ranson criteria,38 Balthazar score (or CT
severity index),39 and Glasgow criteria.40
Papachristou et al36 compared BISAP with
the other traditional multifactorial scoring sys-
tems and found it to have similar test perfor-
mance characteristics for predicting mortality
with clinically relevant and easily obtainable
components. Table 336 outlines the BISAP
scoring system. The downside to the currently
available predicting models is that it has not
been validated for predicting outcomes such
as length of hospital stay, need for intensive
care unit care, or need for intervention.
The initial management of a patient with
PEP centers on supportive care with aggressive
fluid resuscitation, pain control, and nutri-
tional support. Acute pancreatitis typically re-
sults in significant intravascular loss; therefore,
aggressive intravenous hydration should be at
least 250 to 300 mL/h (in the absence of
concomitant cardiac or renal comorbidities).;92(3):434-448 n http://dx.doi.org/10.1016/j.mayocp.2016.10.028
www.mayoclinicproceedings.org
TABLE 3. Bedside Index for Severity in Acute Pancreatitis (BISAP) Scoring
System and Associated Mortality36
Component (1 point for each present) Points Observed mortality (%)
d Blood urea nitrogen >25 mg/dL 0 0.1
d Impaired mental status 1 0.4
d Systemic inflammatory response 2 1.6
d Age >60 y 3 3.6
d Pleural effusion 4 7.4
5 9.5
SI conversion factor: To convert blood urea nitrogen values to mmol/L, multiply by 0.357.
THE SCOPE OF POST-ERCP PANCREATITISHydration should be adjusted based on clin-
ical assessment and titrated to hematocrit
and blood urea nitrogen values.41 As with
other cases of acute pancreatitis, pain control,
nutritional support, and monitoring for
infection are paramount. Details regarding
the management and complications of acute
pancreatitis are beyond the scope of this article
but are discussed in depth elsewhere.37,41
PREVENTION OF PEP
Pharmacologic Agents
During the past 3 decades, nearly 100 RCTs have
aimed to identify potential pharmacologic
agents to use for the chemoprevention of PEP,
with largely disappointing results. The ideal
pharmacologic agent should be short-acting,
well-tolerated with a low adverse effect profile,
and, most importantly, highly efficacious in
reducing PEP. Thus far, clinical trials have had
inadequate sample sizes andnegative, conflicting,
or inconclusive results. In addition, the promise
of a previous positive meta-analysis of agents42
that were subsequently disproved by further clin-
ical investigation43 further amplifies the pessi-
mism surrounding PEP chemoprevention.
Nonsteroidal Anti-inflammatory Drugs
To date, clinical data supporting the use of
nonsteroidal anti-inflammatory drugs (NSAIDs)
for PEP have renewed hope in chemopreven-
tion. The NSAIDs inhibit several mediators of
the inflammatory cascade that are thought to
play a role in the pathogenesis of acute pancre-
atitis, namely, prostaglandins and phospholi-
pase A-2.44 Initial data from 2003-2008
evaluating the chemoprotective effects of
NSAIDs (single-dose rectal indomethacin or
diclofenac) reported conflicting, albeit encour-
aging, results.45-47 A subsequent meta-analysis
by Elmunzer et al,48 which totaled 912 patients,
found that patients who received NSAIDs in the
periprocedural period were 64% less likely to
develop pancreatitis and 90% less likely to
develop moderate to severe pancreatitis. The
pooled analysis found a number needed to treat
(NNT) to prevent 1 episode of pancreatitis of 15.
In addition, there were no adverse events attrib-
uted to NSAID therapy in any of the clinical tri-
als included. Despite the overwhelmingly
positive results of this meta-analysis, there was
not a push for NSAID use in PEP prevention.Mayo Clin Proc. n March 2017;92(3):434-448 n http://dx.doi.org/10
www.mayoclinicproceedings.orgThis sparked a large-scale, multicenter RCT by
Elmunzer et al49 totaling 602 patients random-
ized to receive single-dose rectal indomethacin
or placebo immediately after ERCP. The rates
of PEP in NSAID-treated patients and placebo-
treated patients were 9.2% and 16.9%, respec-
tively (P¼.005). The rates of moderate to severe
pancreatitis in NSAID-treated patients and
placebo-treated patients were 4.4% and 8.8%,
respectively (P¼.03). Last, the use of rectal indo-
methacin was associated with a 7.7% absolute
risk reduction (NNT¼13) and a 46% relative
risk reduction in PEP (P¼.005), which led the
investigators to conclude that rectal indometh-
acin therapy significantly reduces the incidence
of PEP in high-risk patients. Subsequent meta-
analyses have reaffirmed these findings,50-52
and, thus, the use of 100mg of rectal indometh-
acin or diclofenac has become the standard of
care in all high-risk patients.53
A recent publication has cast a doubt on
the utility of NSAIDs for the prevention of
PEP.54 Levenick et al54 performed a single-
center, prospective, double-blind, placebo-
controlled trial evaluating the efficacy of
prophylactic indomethacin use for all patients
undergoing ERCP, including those at average
risk for PEP. The trial included 449 consecu-
tive patients who underwent ERCP from
March 1, 2013, through December 31, 2014,
with approximately 70% of the cohort at
average risk for PEP. During the procedure,
participants were randomized in a 1:1 manner
to receive either a single dose of 100 mg of
indomethacin rectally (n¼223) or a placebo
suppository (n¼226), with the development
of PEP as the primary end point (defined as
new upper abdominal pain, 3ULN elevation
of lipase levels, and hospitalization after ERCP
for 2 consecutive nights). Sixteen patients.1016/j.mayocp.2016.10.028 437
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438(7.2%) in the indomethacin cohort and 11
(4.9%) in the placebo cohort went on to
develop PEP, which was not significant
(P¼.33).
There are a variety of reasons why the
findings by Levenick et al54 refuted those of
the multicenter trial by Elmunzer et al.49 First
and foremost, the patient population in the
multicenter trial49 greatly differed from that
in the single-center study by Levenick et al.54
Most patients in the trial by Elmunzer et al
were women with a clinical suspicion of
sphincter of Oddi dysfunction, a subset of pa-
tients who are, by definition, at high-risk for
PEP.49 In contrast, there was a relatively
even split between female and male patients
in the trial by Levenick et al,54 with relatively
few patients suspected of having sphincter of
Oddi dysfunction (14 of 449 patients). Sec-
ond, the number of patients who received pro-
phylactic duct stents was substantially higher
in the trial by Elmunzer et al49 (w80% of all
patients) compared with the trial by Levenick
et al54 (w15% of all patients). Coupled, these
2 factors might account for the different out-
comes seen in the 2 trials.
Protease Inhibitors
The activation and propagation of proteases,
namely, trypsin, is one of the inciting events
in the development of acute pancreatitis.17
Protease inhibitors prevent the activation of
trypsin, and, thus, several synthetic protease
inhibitors have been studied in the prevention
of PEP, namely, gabexate, ulinastatin, and
nafamostat mesylate.
Manes et al55 performed a multicenter,
prospective RCT evaluating the use of gabex-
ate mesylate in 608 patients (group A ¼ 500
mg within 1 hour before ERCP [n¼203],
group B ¼ 500 mg within 1 hour after
ERCP [n¼203], or group C ¼ saline solution
[n¼202]) to evaluate its efficacy on the inci-
dence of PEP. They found the incidence of
pancreatitis to be 3.9%, 3.4%, and 9.4% in
groups A, B, and C, respectively (P<.01).
Thus, the investigators suggested adminis-
tering gabexate mesylate after ERCP in patients
recognized to be at high risk for PEP. A similar
study by Xiong et al56 found a significant
reduction in the incidence of PEP in patients
pretreated with gabexate mesylate (continuous
intravenous infusion of 300 mg of gabexateMayo Clin Proc. n March 2017mesylate dissolved in 500 mL of Ringer solu-
tion [n¼97] at 111 mL/h, starting 30 minutes
before the procedure and continuing for up to
4 hours after the procedure) compared with
placebo (n¼96) (3.1% vs 10.5%, respectively;
P¼.04). The results suggested that a 4.5-hour
infusion of gabexate mesylate could prevent
PEP.56 Conversely, 2 separate large, multi-
center RCTs by Andriulli et al evaluating the
efficacy of short-term (totaling 2.5 hours,
starting 30 minutes before the procedure and
continuing for up to 2 hours after the proced-
ure)57 and long-term (totaling 6.5 hours, start-
ing 30 minutes before the procedure and
continuing for up to 6 hours after the proced-
ure)58 administration of gabexate mesylate
found gabexate mesylate to be ineffective in
reducing the incidence of PEP compared
with placebo. The heterogeneity present in
the available studies led to a subsequent
meta-analysis of 5 high-quality studies.43 The
rates of PEP in patients treated with gabexate
mesylate and controls were 4.8% and 5.7%,
respectively (P¼.34). In addition, the pooled
data produced no significant effect for either
short-term (<6 hours) or long-term (>12
hours) administration of gabexate mesylate.
One of the major pitfalls to gabexate mesy-
late use is its extremely short half-life, hence
the need for prolonged infusions over several
hours.59 Ulinastatin and nafamostat mesylate
are 2 synthetic protease inhibitors that offer
a longer half-life than gabexate mesylate. Uli-
nastatin has a half-life of approximately 33 mi-
nutes and, as a result, can be given as a bolus
injection.60 Tsujino et al61 evaluated the effi-
cacy of ulinastatin for the prevention of PEP
in a large, multicenter RCT where 406 patients
were randomized to receive ulinastatin
(n¼204) (150,000-U intravenous infusion
for 10 minutes immediately before ERCP) or
placebo (n¼202). The rate of PEP in patients
who received ulinastatin vs placebo was
2.9% vs 7.4% (P¼.041). There were no re-
ported adverse effects related to the medica-
tion in the ulinastatin group, which led the
investigators to conclude that short-term
administration of ulinastatin decreases the
overall incidence of PEP. A subsequent study
by Yoo et al62 randomized 227 patients,
identified during ERCP to be at high risk for
PEP, to receive either ulinastatin (n¼119)
(100,000 U) or placebo (n¼108) immediately
;92(3):434-448 n http://dx.doi.org/10.1016/j.mayocp.2016.10.028
www.mayoclinicproceedings.org
THE SCOPE OF POST-ERCP PANCREATITISafter the procedure. They found there to be no
significant differences between the ulinastatin-
treated and placebo cohorts (rates of pancrea-
titis were 5.6% and 6.7%, respectively), which
led the investigators to conclude that low-dose
treatment with ulinastatin immediately after
ERCP did not influence the incidence of PEP
in high-risk patients. This study was included
in a meta-analysis that totaled 7 RCTs
comparing ulinastatin with placebo (n¼5)
and ulinastatin with gabexate mesylate
(n¼2).63 This meta-analysis found that ulinas-
tatin reduced the incidence of PEP (odds ratio
[OR]¼0.53; 95% CI, 0.31-0.89; P¼.02); how-
ever, subsequent sensitivity and subgroup
analyses did pool conflicting results. This led
the investigators to conclude that ulinastatin
shows some promise in preventing PEP for
patients at average risk when given intrave-
nously at a dose of 150,000 U or greater just
before ERCP.
Nafamostat mesylate has a half-life nearly
20 times longer and a potency up to 100
times greater than gabexate mesylate.64 Three
RCTs, to date, have evaluated the use of nafa-
mostat mesylate in decreasing the incidence
of PEP.65-67 The first comes from Choi
et al,65 whose large single-center RCT ran-
domized 704 patients to receive nafamostat
mesylate (n¼354) (20 mg of nafamostat
mesylate in 500 mL of 5% dextrose solution)
or placebo (n¼350). There was a significant
difference in the incidence of PEP in the nafa-
mostat mesylateetreated cohort compared
with the placebo group (3.3% vs 7.4%,
respectively; P¼.004). A prospective RCT by
Yoo et al66 reported the benefit of nafamostat
mesylate in reducing the incidence of PEP.
Last, Park et al67 evaluated the use of high-
dose nafamostat mesylate (50 mg), with
high-risk patients in mind, in decreasing the
incidence of PEP. A total of 608 patients
were randomized to receive an infusion of
20 mg of nafamostat mesylate, 50 mg of nafa-
mostat mesylate, or placebo; they found a
significant difference in the incidence of
PEP with or without nafamostat mesylate
(4.0% vs 5.1% vs 13.0%, respectively;
P<.001). Subgroup analysis revealed that
the rate of PEP was significantly different in
low-risk patients receiving nafamostat mesy-
late compared with controls; however, this
was not seen in high-risk patients.Mayo Clin Proc. n March 2017;92(3):434-448 n http://dx.doi.org/10
www.mayoclinicproceedings.orgAlthough protease inhibitors have shown
some promise, they are costly, require extremely
high NNTs to prevent a single episode of PEP
(gabexate ¼ 33 and ulinastatin ¼ 29),68 and
possibly necessitate hospital admission for
medication infusion, all of which may preclude
their mainstream use.
Somatostatin and Octreotide
Somatostatin is a natural hormone that
potently inhibits the pancreatic exocrine secre-
tion, which is thought to play a pivotal role in
the pathogenesis of acute pancreatitis by
causing autodigestion of the organ.69 A
meta-analysis by Andriulli et al43 included 9
high-quality trials evaluating the effect of so-
matostatin on the incidence of PEP. Pooled
data found there to be no significant effect of
somatostatin on the development of PEP
(7.3% of controls vs 5.3% of treated patients;
OR¼0.73; 95% CI, 0.54-1.006), irrespective
of length of somatostatin infusion (short, <6
hours; long, 12 hours). A meta-analysis by
Rudin et al70 (7 RCTs including 3130 pa-
tients), however, reported conflicting results:
they found there to be a significant reduction
of PEP with long-term somatostatin infusion
(defined as 12 hours).
Octreotide is a synthetic analogue of so-
matostatin with a longer half-life. A meta-
analysis by Andriulli et al,42 which included
10 studies, found there to be no effect of octreo-
tide on the development of PEP. Subsequent
RCTs have also reported conflicting results.71,72
Thomopoulos et al71 evaluated whether an
increased dosage of octreotide would reduce
the incidence of PEP. This RCT randomized
201 patients to receive 500 mg of octreotide
(n¼100), given 3 times daily subcutaneously
starting 24 hours before ERCP, or placebo
(n¼101). They found the incidence of PEP to
be significantly lower in the octreotide-treated
group compared with the placebo group
(2.0% vs 8.9%, respectively; P¼.03), which
led the investigators to support the use of 24-
hour prophylaxis with high-dose octreotide in
PEP prevention. Conversely, a multicenter
RCT by Testoni et al,72 which randomized
114 patients to receive 200 mg of octreotide
(n¼58), given 3 times daily subcutaneously
starting 24 hours before ERCP, or placebo
(n¼56), found there to be no significant differ-
ence in the rates of PEP (12.0% vs 14.3%,.1016/j.mayocp.2016.10.028 439
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440respectively) or in the severity of pancreatitis,
which led the investigators to conclude that
24-hour prophylaxis with octreotide is ineffec-
tive in preventing PEP. A subsequent meta-
analysis by Zhang et al,73 which included 18
RCTs, examined the effects of octreotide at
different dosages on PEP. They used a dose of
500 mg as their cutoff value, and the rate of
PEP was analyzed using a fixed effects model.
They found that at doses of 500 mg or greater,
there was a significant difference in the inci-
dence of PEP (3.4% in the octreotide-treated
group vs 7.5% in the control group; pooled
OR¼0.45; 95% CI, 0.28-0.73; P¼.001,
NNT¼25). In patients treated with a dose less
than 500 mg, there was no difference in the rates
of PEP, which led the authors to conclude that
octreotide is effective in preventing PEP, but
only at sufficient doses (ie, 500 mg).
Although octreotide shows promise, the
optimal timing and dosage of administration
remains an area for further study. Current
guidelines do not recommend octreotide for
the prophylaxis of PEP but state that future
studies should evaluate its efficacy at dosages
of 500 mg or greater.53
Nitroglycerin
Nitroglycerin is a smooth muscle relaxant
thought to promote pancreatic blood flow and
decrease sphincter of Oddi pressures.74 To
date, there has been conflicting data regarding
the use of nitroglycerin, with 3 placebo-
controlled RCTs reporting a significant reduc-
tion in the incidence of PEP75-77 and 4 reporting
no benefit.78-81 Recently, however, Sotoudeh-
manesh et al evaluated combination therapy
with rectal indomethacin and sublingual ni-
trates in the prevention of PEP, with patients
at high risk for PEP in mind (>80%).82 In this
double-blind RCT, 300 patients were random-
ized to receive 100 mg of rectal indomethacin
plus 5 mg of sublingual nitrate, or 100 mg
of rectal indomethacin plus sublingual placebo
before ERCP. They found the rates of
PEP to be significantly decreased in patients
who received combination indomethacin-
nitroglycerin therapy compared with the
indomethacin-placebo cohort (6.7% vs 15.3%,
respectively; P¼.02). Note that a substantial
portion of the study sample did not receive a
pancreatic duct stent. They concluded that
combination therapy with rectal indomethacinMayo Clin Proc. n March 2017and sublingual nitrates before ERCP was signif-
icantly more likely to reduce the incidence of
PEP compared with rectal indomethacin ther-
apy alone. Nitrates have not yet made their
way into guidelines53; however, they should
be considered as adjunctive therapy to rectal
NSAIDs in high-risk patients who do not
receive a prophylactic pancreatic duct stent.
Further larger-scale, multicenter RCTs are
necessary to establish the role of nitrates in
decreasing the incidence of PEP.
Allopurinol and N-acetylcysteine
Capillary endothelial injury, mediated by
oxygen-derived free radicals, is thought to
play a pivotal role in the pathogenesis of acute
pancreatitis.83 Xanthine oxidase is thought to
generate oxygen-derived free radicals via cata-
lyzing the conversion of hypoxanthine to
xanthine. Allopurinol, a xanthine oxidase inhib-
itor, is postulated to mediate this pathway, thus
reducing the incidence of PEP. However, the
early success of canine models84 did not trans-
late into human studies, which had conflicting
results.85-88 A pooled meta-analysis by Zheng
et al,89 which included 6 RCTs totaling 1554
patients, evaluated the efficiency of allopurinol
in the prevention of PEP. The ORs for allopu-
rinol were 0.74 (95% CI, 0.37-1.48; P¼.40)
for PEP and 0.88 (95% CI, 0.37-2.11; P¼.78)
for severe PEP, which led the authors to
conclude that allopurinol cannot prevent the
incidence of PEP and thus not to recommend
its use in the prophylaxis of PEP.
N-acetylcysteine is a free radical scavenger,
which has shown benefit in chemical-induced
pancreatitis in mouse models.90 However, this
benefit did not translate to human studies.91,92
Katsinelos et al91 evaluated the efficacy of intra-
venous N-acetylcysteine for the prevention of
PEP by randomizing 256 patients to receive
intravenousN-acetylcysteine (70mg/kg 2 hours
before ERCP and 35 mg/kg at 4-hour intervals
for 24 hours after the procedure) or placebo
with normal saline. The incidence of PEP was
12.1% in the N-acetylcysteine group and 9.6%
in the placebo group, which led the authors to
conclude that there was no beneficial effect of
N-acetylcysteine on the incidence and severity
of PEP. A subsequent study by Milewski
et al92 evaluated the effect of N-acetylcysteine
on the incidence of PEP by randomizing 106
patients to receive N-acetylcysteine (n¼55)
;92(3):434-448 n http://dx.doi.org/10.1016/j.mayocp.2016.10.028
www.mayoclinicproceedings.org
THE SCOPE OF POST-ERCP PANCREATITIS(two 600-mg doses orally 24 and 12 hours
before ERCP and 600 mg intravenously, twice
a day for 2 days after ERCP) or placebo with
isotonic saline (n¼51). They found no signifi-
cant difference in the rate of PEP between the
2 groups, which led to the conclusion that the
use of N-acetylcysteine has no chemoprotective
effect against PEP.
Procedural Techniques
Many of the procedure-related risk factors
described previously herein, although predis-
posing to PEP, are often unavoidable. Therefore,
methodical and precise technical practices are a
must during ERCP to minimize the risk of PEP.
Biliary Access
As previously described, difficult cannulation
and pancreatic duct injection are independent
procedure-related risk factors for PEP. As
such, selective cannulation of the common
bile duct (CBD) via insertion of a guidewire
and limited injection of contrast into the
pancreatic duct are likely to decrease the risk
of PEP.
Normally, a guidewire with a hydrophilic
tip (either 0.032 or 0.025 inches in diameter)
is preloaded into a papillotome. The papillo-
tome is then oriented such that it is in the 11-
o’clock position on the papilla, and flexed in
the presumed axis of the bile duct. The direct
contact method refers to minimal insertion
(approximately 2-3 mm) of the papillotome
into the ampulla with subsequent passage of
the guidewire, under fluoroscopic guidance,
through the CBD until it is seen to enter the
bile duct. If at this point the pancreatic duct is
cannulated, the guidewire can simply be with-
drawn and repositioned in an attempt to
cannulate the CBD. A recent meta-analysis by
Tse et al,93 composed of 12 RCTs and totaling
3450 participants, evaluated the effectiveness
and safety of the guidewire-assisted cannulation
technique compared with conventional
contrast-assisted cannulation for the prevention
of PEP. They found a significant reduction in
rates of PEP (relative risk [RR] ¼ 0.51; 95%
CI, 0.32-0.82), greater primary cannulation
success (RR ¼ 1.07; 95% CI, 1.00-1.15), and
less need for precut sphincterotomy (RR ¼
0.75; 95% CI, 0.60-0.95) with guidewire-
assisted cannulation compared with the
traditional contrast-assisted cannulation. InMayo Clin Proc. n March 2017;92(3):434-448 n http://dx.doi.org/10
www.mayoclinicproceedings.orgaddition, there were no increases in other
ERCP-related complications. This led to the
conclusion that the guidewire-assisted cannula-
tion technique seems to be themost appropriate
first-line cannulation technique because it
increases the primary cannulation rate and re-
duces the overall risk of PEP.
If initial cannulation attempts are unsuc-
cessful or if the pancreatic duct is repeatedly
cannulated, it is appropriate to consider switch-
ing to another method. Notably, the definition
of difficult cannulation at present is an imper-
fect science with substantial variability among
studies. The varying definitions of difficult
cannulation have included failure to achieve
biliary access after attempting to do so for longer
than 10 minutes,94 more than 5 unintentional
pancreatic cannulations,94 and 7 or more at-
tempts required to ultimately achieve cannula-
tion.95 Pancreatic guidewire-assisted biliary
cannulation is a technique that can be effectively
used for biliary access, particularly if the pancre-
atic duct is repeatedly cannulated unintention-
ally and relatively easily.96 A pancreatic
guidewire is left in place in the pancreatic
duct, which straightens the ampulla and acts
as a barrier to prevent further pancreatic duct
cannulation, and a second guidewire is passed
through a papillotome, allowing for biliary can-
nulation alongside the existing pancreatic wire.
Ito et al97 investigated the frequency of PEP after
pancreatic guidewire placement in achieving
cannulation of the bile duct during ERCP.
Pancreatic guidewire placement was
performed in 113 patients where bile duct can-
nulation was found to be difficult (defined as
unsuccessful cannulation within 15 minutes).
Selective biliary cannulation with pancreatic
guidewire placement was achieved in 72.6%
of patients, with PEP occurring in 12.3%.
Notably, prophylactic placement of a pancreatic
stent (discussed in detail later herein) was
attempted in 56.6% of patients (n¼64), of
which only 3 (4.7%) developed mild pancrea-
titis. In contrast, of the 43.4% of patients
(n¼49) without pancreatic stent placement,
11 (22.4%) developed mild pancreatitis. This
led the authors to conclude that pancreatic
guidewire placement is useful to achieve selec-
tive biliary cannulation and that subsequent
pancreatic duct stenting can reduce the inci-
dence of PEP. This role of prophylactic pancre-
atic duct placement in the setting of pancreatic.1016/j.mayocp.2016.10.028 441
MAYO CLINIC PROCEEDINGS
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contention. Several experts believe that guide-
wire introduction into the pancreatic duct in
and of itself is not responsible for increased rates
of PEP despite data that found that manipula-
tion of the pancreatic duct using a guidewire
increased rates of PEP.28,98,99 In addition, a
recent prospective RCT by Ito et al100 evaluated
the prophylactic effect of pancreatic duct stent-
ing on the frequency of PEP in patients who un-
derwent pancreatic duct guidewire placement
to achieve biliary cannulation. Seventy patients
who underwent pancreatic duct guidewire
placement to achieve selective biliary cannula-
tion were randomized to receive a pancreatic
duct stent (n¼35) or no stent (n¼35). The
overall incidence of PEP was significantly lower
in patients who received a pancreatic duct stent
compared with those in the no-stent group
(2.9% vs 22.9%, respectively), which led the au-
thors to conclude that pancreatic duct stenting
after pancreatic guidewire placement for selec-
tive biliary cannulation is recommended to
reduce the incidence of PEP.
Precut sphincterotomy refers to a variety of
endoscopic techniques, namely, needle-knife
sphincterotomy, fistulostomy, or transpancre-
atic sphincterotomy or septomy, used to gain
access into the bile duct when standard cannu-
lation techniques have proved unsuccessful.
Initial studies have found this technique to be
an independent risk factor for the development
of PEP,30,101 but it is more likely that the
increased risk of PEP stems from the prolonged
cannulation attempts with resultant papillary
edema, stressing the importance of implement-
ing alternative techniques earlier rather than
later to reduce the incidence of PEP. This point
is illustrated by a recent meta-analysis by
Cennamo et al102 that included 6 RCTs totaling
966 patients comparing cannulation and
adverse event rates of early precut implementa-
tion with persistent attempts by conventional
techniques. They found the rates of PEP to be
2.5% in patients randomized to early precut
compared with 5.3% in patients from the
persistent attempts cohort (OR¼0.47; 95%
CI, 0.24-0.91). Several prospective trials, retro-
spective trials, and other meta-analyses have
also reported that the use of precut sphincterot-
omy, when implemented early and successful,
is not an independent risk factor for the devel-
opment of PEP,103-106 and when performed byMayo Clin Proc. n March 2017high-volume, qualified endoscopists can in-
crease rates of primary cannulation and ulti-
mately reduce the risk of PEP.107
Prophylactic Placement of Pancreatic Stents
Pancreatic stents are thought to reduce the risk
of PEP by preserving pancreatic drainage and
relieving pancreatic ductal hypertension that
might otherwise be impaired from papillary
edema or spasm of the sphincter of Oddi,
respectively. There have been several RCTs
evaluating prophylactic pancreatic stent place-
ment and the subsequent incidence of PEP
(Table 4).100,108-129
It is important to be mindful of the disad-
vantages associated with prophylactic pancre-
atic stent placement. Placement of a pancreatic
stent can be technically difficult and can incite
further injury to the pancreatic orifice, resulting
in an increased risk of PEP without any ductal
decompression.121,122 In addition, given the
fact that stent migration and duct perforation
occur in approximately 4% of patients,123
follow-up evaluation is required to ensure pas-
sage or removal of the stent, potentially subject-
ing the patient to an additional procedure. Last,
the optimal duration for stent retention remains
unknown, but one should be aware that pro-
longed retention has been found to induce
ductal changes, which resemble those of chronic
pancreatitis, although the long-term clinical sig-
nificance of these changes remain unknown.124
Despite the potential pitfalls, prophylactic stent
placement is widely accepted as an effective
means of preventing PEP125,126 and is recom-
mended by consensus guidelines, in particular
for high-risk patients.53
Aggressive Intravenous Hydration
Another point of contention is the use of aggres-
sive intravenous fluid hydration in PEP preven-
tion, which has long been the mainstay of
treatment of acute pancreatitis irrespective of
the underlying etiology.37 A retrospective study
by DiMagno et al,127 which included 6505 pa-
tients who underwent 8264 ERCPs, investi-
gated whether large periprocedural volumes
influenced the severity of PEP.Of these patients,
211 developed PEP (48 mild, 141 moderate,
and 22 severe), with available data for fluid vol-
ume for 173 patients with PEP. In a univariable
and multivariable analysis, larger periproce-
dural fluid volume was found to be protective;92(3):434-448 n http://dx.doi.org/10.1016/j.mayocp.2016.10.028
www.mayoclinicproceedings.org
TABLE 4. Summary of RCTs Evaluating Placement of Prophylactic Pancreatic Stents
Reference, year
Participants
(No.) Pancreatic stent
Rates of PEP,
stent/nonstent (%) P value
Cha et al,108 2013 151 5-7 Fr and 2-2.5 cm internally and externally flanged straight or
internally flanged with an external three-quarter pigtail stent
4.3/21.3 .03
Fazel et al,109 2003 76 5 Fr nasopancreatic catheter tube or double-flanged 5 Fr and
2-cm-long stent
5/28 <.05
Harewood et al,110 2005 19 Single-flanged 5 Fr and 3- to 5-cm-long straight polyethylene stent 0/33 .02
Kawaguchi et al,111 2012 120 Double-flanged to duodenal side, 5 Fr and 3-cm-long polyethylene
stent
1.7/13.3 .03
Ito et al,100 2010 70 5 Fr and 4-cm-long stent with duodenal pigtail 2.9/23
Lee et al,112 2012 101 Unflanged 3 Fr and 4-, 6-, or 8-cm-long duodenal pigtail stent 12/29.4 .03
Pan et al,113 2011 40 5 Fr single pigtail stent 20/70 <.01
Patel et al,114 1999 36 5 Fr stent 11/33 <.05
Sherman et al,115 1995 104 5-7 Fr and 2- to 2.5-cm-long stent 2.2/21.3 .004
Smithline et al,116 1993 93 Double-flanged 5-7 Fr and 2- to 2.5-cm-long polyethylene stent 14/18 .23
Sofuni et al,117 2011 426 Double-flanged to duodenal side, 5-7 Fr and 3-cm-long
polyethylene stent
7.9/15.2 .02
Sofuni et al,118 2007 201 Double-flanged to duodenal side, 5 Fr and 3-cm-long polyethylene
stent
3.2/13.6 .02
Tarnasky et al,119 1998 80 5-7 Fr and 2- to 2.5-cm-long stent 7/26 .03
Tsuchiya et al,120 2007 64 Unflanged 5 Fr and 3- to 4-cm-long duodenal pigtail stent 3.1/12.5 >.05
Fr ¼ French; PEP ¼ posteendoscopic retrograde cholangiopancreatography pancreatitis; RCT ¼ randomized controlled trial.
THE SCOPE OF POST-ERCP PANCREATITISagainst moderate to severe PEP. A retrospective
study by Sagi et al128 looked to see whether
there was any correlation between early intrave-
nous volume infusion (defined as during the
first 24 hours after ERCP) and length of PEP.
The retrospective study included 72 patients,
with the primary outcome being severity of
PEP (defined as length of hospitalization
according to consensus guidelines [Table 2]).
Of the 72 patients, 41 (56.9%) had mild PEP
and 31 (43.1%) had moderate or severe PEP.
Patients with mild PEP received significantly
greater intravenous volume infusion during
the first 24 hours compared with those with
moderate or severe PEP (2834 mL vs 2044
mL, respectively; P<.02). This led the authors
to conclude that in patients with PEP, greater
intravenous volume infusion within the first
24 hours after ERCP is associated with reduced
length of hospitalization.
The choice of intravenous fluid is also
important in PEP prevention. Mechanistically
speaking, lactated Ringer solution closely re-
sembles physiologic pH and, thus, may
attenuate acidosis that promotes zymogen acti-
vation and resultant pancreatic inflammation
as previously described. A recent pilot RCT
by Buxbaum et al129 determined whetherMayo Clin Proc. n March 2017;92(3):434-448 n http://dx.doi.org/10
www.mayoclinicproceedings.orgaggressive periprocedural hydration with
lactated Ringer solution reduced the incidence
of PEP in 62 patients. Patients were randomly
assigned (2:1) to receive aggressive hydration
with lactated Ringer solution (3 mL/kg per
hour during the procedure, 20-mL/kg bolus
after the procedure, and 3 mL/kg per hour
for 8 hours after the procedure; n¼39) or
standard hydration with the same solution
(1.5 mL/kg per hour during the procedure
and for 8 hours after the procedure; n¼23).
They found that none of the patients in the
aggressive hydration group developed PEP,
whereas 17% of patients in the standard hy-
dration cohort developed PEP (P¼.02). There
was no evidence of volume overload in these
patients, suggesting that aggressive intrave-
nous hydration with lactated Ringer solution
can safely reduce the development of PEP.
CONSIDERATIONS FOR THE FUTURE OF
PEP PREVENTION
Despite the advances in PEP prevention, there
still are several questions that remain unan-
swered. Note that the large-scale, multicenter
RCT by Elmunzer et al49 underemphasized
one key concept as outlined by Baron et al.130
Elmunzer et al placed prophylactic pancreatic.1016/j.mayocp.2016.10.028 443
PEP prevention
Chemoprophylaxis
Prophylactic pancreatic duct stent
Procedural technique
Patient selection
1.   Administer rectal
     indomethacin or diclofenac
     for all high-risk cases
2.   Consider rectal indomethacin
     or diclofenac for all low and
     average risk cases
1.   Employ a wire-guided
     cannulation technique
2.   Implement alternative
     technique early in the case in
     the event of difficult biliary
     cannulation
1.   ERCP should be almost
     exclusively therapeutic
     procedure
2.   Utilize MRCP and / or EUS as
     diagnostic tools 
3.   Ideally performed at a
     tertiary care center with an
     experienced endoscopist
1.   Administer in conjunction
     with rectal indomethacin or
     diclofenac in all high-risk cases
2.   Consider the risk-benefit
     ratio in all challenging cases
FIGURE. Comprehensive approach to PEP prevention. ERCP¼ endoscopic retrograde cholangiopancreatography; EUS¼ endoscopic
ultrasound; MRCP ¼ magnetic resonance cholangiopancreatograph; PEP ¼ postdendoscopic retrograde cholangiopancreatography
pancreatitis.
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444stents in more than 80% of study patients,
among whom there was clinical suspicion of
sphincter of Oddi dysfunction (known to
have a high risk of PEP). In this subset
(sphincter of Oddi dysfunction type III), indo-
methacin was not protective, suggesting that
the reported effect for indomethacin may not
be robust enough to overcome operator-
dependent effects. A subsequent post hoc anal-
ysis by Elmunzer et al131 investigated whether
rectal indomethacin therapy could prevent
PEP and any potential cost savings. They retro-
spectively classified participants from a previ-
ous large-scale, multicenter study49 into 4
prevention groups: (1) those who received no
prophylaxis, (2) those who had a prophylactic
pancreatic duct stent placed, (3) those who
received only rectal indomethacin, and (4)
those who had a prophylactic pancreatic duct
stent placed and received rectal indomethacin.
Multivariate logistic regression and economic
analysis comparing the costs associated with
using rectal indomethacin alone, placing solely
a prophylactic pancreatic duct stent, or the
combination of both found that rectal indo-
methacin therapy alone seemed to be more
effective in PEP prevention than the otherMayo Clin Proc. n March 2017strategies used. In addition, rectal indometh-
acin use alone was a cost-saving strategy that
could save more than $150 million in the
United States. This led the authors to conclude
that there may be a role for the sole use of
prophylactic rectal indomethacin in patients
undergoing high-risk ERCP, which could also
substantially reduce health care costs.
To date, there is no available data from large-
scale, multicenter RCTs directly comparing
rectal NSAIDs with placement of a prophylactic
pancreatic duct stent. A network meta-analysis
by Akbar et al,50 which totaled 29 studies (22
of pancreatic duct stents and 7 of NSAIDs),
found that the use of rectal NSAIDs alone was
superior to pancreatic duct stents alone in the
prevention of PEP (OR¼0.48; 95% CI, 0.26-
0.87). This led the authors to conclude that
rectal NSAIDs are superior to prophylactic
pancreatic duct stents alone in the prevention
of PEP and should be considered first-line ther-
apy in selected patients.
These data raise several key questions: (1)
Should everyone receive rectal NSAIDs irre-
spective of patient- or procedure-related risk
factors as outlined by the European Society
of Gastrointestinal Endoscopy53 or can we;92(3):434-448 n http://dx.doi.org/10.1016/j.mayocp.2016.10.028
www.mayoclinicproceedings.org
THE SCOPE OF POST-ERCP PANCREATITISrisk-stratify patients? Recent data from a pro-
spective, double-blind RCT totaling 449
consecutive patients by Levenick et al54 found
that rectal indomethacin therapy does not uni-
versally prevent PEP. These data suggest that
there may be a specific subset of patients who
respond favorably to rectal indomethacin
therapy, requiring further research. (2) In
high-risk patients in whom biliary cannulation
is immediately achieved, do we need to pursue
pancreatic cannulation for stent placement or
would rectal NSAID use be sufficient in PEP
prevention? (3) Should we aggressively hydrate
all patients with lactated Ringer solutions?
The Figure outlines a comprehensive app-
roach and meaningful use of risk- stratification
information and potential pharmacologic or
procedural techniques that can be used to
reduce the risk of PEP.CONCLUSION
It is imperative for the clinical endoscopist to be
cognizant of patient- and procedure-related risk
factors to formulate a comprehensive risk
reduction strategy to minimize the risk of PEP.
Because patient-related risk factors cannot be
modified, clinicians should analyze the risk:be-
nefit ratio in each patient being considered for
ERCP. Several questions remain unanswered
regarding PEP prevention, in both the pharma-
cologic and procedural realms, that are
currently under investigation.Abbreviations and Acronyms: BISAP = bedside index for
severity in acute pancreatitis; CBD = common bile duct; CT
= computed tomography; ERCP = endoscopic retrograde
cholangiopancreatography; Fr = French; NNT = number
needed to treat; NSAID = nonsteroidal anti-inflammatory
drug; OR = odds ratio; PEP = posteendoscopic retro-
grade cholangiopancreatography pancreatitis; RCT = ran-
domized controlled trial; RR = relative risk; ULN = upper
limit of normal
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